Serum albumin: its relationship to marrow and renal toxicity from platinum-based combination chemotherapy

Gynecol Oncol. 1990 Apr;37(1):93-5. doi: 10.1016/0090-8258(90)90315-c.

Abstract

One hundred and three patients treated with CAP chemotherapy were evaluated to determine the relationship between low prechemotherapy serum albumin (less than 3 g/dl) and low WBC nadir (less than 2000 cells/mm3). Additionally, the relationship of serum albumin to renal toxicity (delta serum creatinine) was examined. Low prechemotherapy serum albumin appears to be a marker for advanced disease, but does not appear to predict marrow or renal toxicity.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Bone Marrow Diseases / blood
  • Bone Marrow Diseases / chemically induced*
  • Cisplatin / administration & dosage
  • Creatinine / blood
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Kidney Diseases / blood
  • Kidney Diseases / chemically induced*
  • Leukocyte Count / drug effects
  • Middle Aged
  • Neoplasm Staging
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / mortality
  • Ovarian Neoplasms / pathology
  • Serum Albumin / metabolism*
  • Survival Rate

Substances

  • Serum Albumin
  • Doxorubicin
  • Cyclophosphamide
  • Creatinine
  • Cisplatin

Supplementary concepts

  • CISCA protocol